Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Oral anticoagulation with edoxaban. Focus on current phase III clinical development.

Ahrens I, Bode C.

Hamostaseologie. 2012;32(3):212-5. doi: 10.5482/HAMO-12-05-0004. Epub 2012 Jul 12.

PMID:
22786687
[PubMed - indexed for MEDLINE]
2.

Edoxaban: a new oral direct factor xa inhibitor.

Camm AJ, Bounameaux H.

Drugs. 2011 Aug 20;71(12):1503-26. doi: 10.2165/11595540-000000000-00000.

PMID:
21861537
[PubMed - indexed for MEDLINE]
3.

Edoxaban tosylate.

[No authors listed]

Am J Cardiovasc Drugs. 2011;11(2):129-35. doi: 10.2165/11533660-000000000-00000. Review.

PMID:
21446778
[PubMed - indexed for MEDLINE]
4.

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.

Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI.

Thromb Haemost. 2010 Sep;104(3):642-9. doi: 10.1160/TH10-02-0142. Epub 2010 Jun 29.

PMID:
20589317
[PubMed - indexed for MEDLINE]
5.

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.

Am Heart J. 2010 Oct;160(4):635-41. doi: 10.1016/j.ahj.2010.06.042.

PMID:
20934556
[PubMed - indexed for MEDLINE]
6.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.

Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S.

Thromb Haemost. 2012 May;107(5):925-36. doi: 10.1160/TH11-08-0566. Epub 2012 Mar 8.

PMID:
22398655
[PubMed - indexed for MEDLINE]
7.

[Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban].

Morishima Y, Shibano T.

Nihon Yakurigaku Zasshi. 2010 Aug;136(2):83-7. Review. Japanese. No abstract available.

PMID:
20702966
[PubMed - indexed for MEDLINE]
8.

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.

Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S.

Thromb Haemost. 2011 Jun;105(6):1080-90. doi: 10.1160/TH10-11-0705. Epub 2011 May 5.

PMID:
21544313
[PubMed - indexed for MEDLINE]
9.

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S.

Thromb Haemost. 2010 Sep;104(3):633-41. doi: 10.1160/TH10-01-0066. Epub 2010 Aug 5.

PMID:
20694273
[PubMed - indexed for MEDLINE]
10.

Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.

Raskob G, B├╝ller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M; Hokusai-VTE Investigators.

J Thromb Haemost. 2013 Jul;11(7):1287-94. doi: 10.1111/jth.12230.

PMID:
23574579
[PubMed - indexed for MEDLINE]
11.

[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].

Sprynger M.

Rev Med Liege. 2013 Oct;68(10):548-51. French.

PMID:
24298731
[PubMed - indexed for MEDLINE]
12.

Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.

Fukuda T, Tsuji N, Honda Y, Kamisato C, Morishima Y, Shibano T.

Thromb Haemost. 2011 Dec;106(6):1062-8. doi: 10.1160/TH11-07-0451. Epub 2011 Sep 22.

PMID:
21946952
[PubMed - indexed for MEDLINE]
13.

Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.

Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, Lee TH, Chen SA.

Thromb Haemost. 2011 Mar;105(3):535-44. doi: 10.1160/TH10-07-0451. Epub 2010 Dec 6.

PMID:
21136011
[PubMed - indexed for MEDLINE]
14.

Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.

Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N, Shibano T.

Thromb Res. 2012 Sep;130(3):514-9. doi: 10.1016/j.thromres.2012.05.008. Epub 2012 May 29.

PMID:
22647432
[PubMed - indexed for MEDLINE]
15.

Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

Zahir H, Matsushima N, Halim AB, He L, Zhang G, Lee F, Worland V, Mendell J.

Thromb Haemost. 2012 Jul;108(1):166-75. doi: 10.1160/TH11-09-0676. Epub 2012 May 25.

PMID:
22628060
[PubMed - indexed for MEDLINE]
16.

Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer?

Wolfram O, Hammwoehner M, Gramley F, Goette A.

Curr Vasc Pharmacol. 2011 May;9(3):350-7. Review.

PMID:
21143166
[PubMed - indexed for MEDLINE]
17.

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.

Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T.

Thromb Haemost. 2012 Feb;107(2):253-9. doi: 10.1160/TH11-09-0668. Epub 2011 Dec 21.

PMID:
22186946
[PubMed - indexed for MEDLINE]
18.

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

Rohatagi S, Mendell J, Kastrissios H, Green M, Shi M, Patel I, Salazar DE.

Thromb Haemost. 2012 Nov;108(5):887-95. doi: 10.1160/TH12-03-0184. Epub 2012 Sep 26.

PMID:
23014669
[PubMed - indexed for MEDLINE]
19.

[Current status and future of anti-Xa inhibitors].

Nagao T.

Rinsho Shinkeigaku. 2011 Nov;51(11):1007-10. Review. Japanese.

PMID:
22277459
[PubMed - indexed for MEDLINE]
20.

Edoxaban for the prevention of thromboembolic events after surgery.

Gras J.

Drugs Today (Barc). 2011 Oct;47(10):753-61. doi: 10.1358/dot.2011.47.10.1709241. Review.

PMID:
22076490
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk